{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:57:57Z","timestamp":1790812677180,"version":"4.1.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Merck Sharp & Dohme LLC"},{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Doravirine\/islatravir (DOR\/ISL) is a 2-drug, single-tablet regimen in clinical development for once-daily treatment of adults living with HIV-1. We examined the impact of baseline resistance-associated mutations (RAMs) in proviral DNA on the response to DOR\/ISL (100\/0.25 mg) in virologically suppressed participants in three phase 3 studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Samples were collected pre-dose from participants in studies P051 (NCT05631093), P052 (NCT05630755), and P054 (NCT05766501) to evaluate RAMs in proviral DNA at baseline. The prevalence of baseline non-nucleoside reverse transcriptase inhibitor (NNRTI) RAMs and M184I\/V, and their impact on virologic suppression (HIV-1 RNA &amp;lt;50 copies\/mL) at week 48, as well as on types of viremia (confirmed HIV-1 RNA \u2265200 copies\/mL, low-level viremia, and transient viremia), was examined. Samples from participants with confirmed HIV-1 RNA \u2265200 copies\/mL or who discontinued from treatment with HIV-1 RNA \u2265200 copies\/mL were assessed for viral drug resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 1227 participants who switched to DOR\/ISL, 323 (26.3%) had baseline NNRTI RAMs and 70 (5.7%) had baseline M184I\/V. At week 48, DOR\/ISL maintained HIV-1 RNA &amp;lt;50 copies\/mL in \u226588% of participants with and\/or without NNRTI RAMs and\/or M184I\/V detected in proviral DNA at baseline. The percentage of participants in each viremia category was comparable with regard to the presence or absence of NNRTI RAMs and\/or M184I\/V. No treatment-emergent resistance to DOR or ISL was observed in the 7 participants who met criteria for postbaseline resistance testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Baseline NNRTI RAMs and M184I\/V in proviral DNA did not impact virologic outcomes through 48 weeks after switching to DOR\/ISL (100\/0.25 mg).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trials Registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov: NCT05631093, NCT05630755, NCT05766501.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiag257","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T11:22:36Z","timestamp":1779794556000},"page":"e466-e476","source":"Crossref","is-referenced-by-count":2,"title":["Switching to Daily Doravirine\/Islatravir (100\/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance\u2013Associated Mutations or M184I\/V in Proviral DNA"],"prefix":"10.1093","volume":"234","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4672-8641","authenticated-orcid":false,"given":"Tracy L","family":"Diamond","sequence":"first","affiliation":[{"name":"Merck & Co., Inc. MRL, , Rahway, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjana","family":"Grandhi","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. MRL, , Rahway, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6724-0676","authenticated-orcid":false,"given":"Monica","family":"Fuszard","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. MRL, , Rahway, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayun","family":"Xu","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. MRL, , Rahway, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uchechukwu","family":"Nwoke","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. MRL, , Rahway, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. MRL, , Rahway, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5247-3044","authenticated-orcid":false,"given":"Stephanie O","family":"Klopfer","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. MRL, , Rahway, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8626-2753","authenticated-orcid":false,"given":"Karen","family":"Eves","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. MRL, , Rahway, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Benner","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. MRL, , Rahway, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3489-4052","authenticated-orcid":false,"given":"Mengchun","family":"Li","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. MRL, , Rahway, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Greaves","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. MRL, , Rahway, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima","family":"Lahoulou","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. MRL, , Rahway, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Kim","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. MRL, , Rahway, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle C","family":"Fox","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. MRL, , Rahway, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Asante-Appiah","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. MRL, , Rahway, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"2026092314200990400_jiag257-B1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1056\/NEJM198707233170401","article-title":"The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial","volume":"317","author":"Fischl","year":"1987","journal-title":"N Engl J Med"},{"key":"2026092314200990400_jiag257-B2","doi-asserted-by":"crossref","first-page":"13596535231201162","DOI":"10.1177\/13596535231201162","article-title":"HIV drug resistance in the era of contemporary antiretroviral therapy: a clinical perspective","volume":"28","author":"Carr","year":"2023","journal-title":"Antivir Ther"},{"key":"2026092314200990400_jiag257-B3","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/cid\/ciu046","article-title":"Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials","volume":"58","author":"Nachega","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2026092314200990400_jiag257-B4","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.jiac.2024.02.012","article-title":"Factors associated with patient satisfaction with antiretroviral therapy in Japan: a cross-sectional, multicenter study","volume":"30","author":"Hikasa","year":"2024","journal-title":"J Infect Chemother"},{"key":"2026092314200990400_jiag257-B5","doi-asserted-by":"crossref","first-page":"e0121621","DOI":"10.1128\/AAC.01216-21","article-title":"Impact of HIV-1 resistance-associated mutations on susceptibility to doravirine: analysis of real-world clinical isolates","volume":"65","author":"Asante-Appiah","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092314200990400_jiag257-B6","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/AAC.04201-14","article-title":"In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways","volume":"59","author":"Feng","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092314200990400_jiag257-B7","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/QAI.0000000000002496","article-title":"Review of doravirine resistance patterns identified in participants during clinical development","volume":"85","author":"Martin","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026092314200990400_jiag257-B8","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1093\/jac\/dkad184","article-title":"Doravirine responses to HIV-1 viruses bearing mutations to NRTIs and NNRTIs under in vitro selective drug pressure","volume":"78","author":"Brenner","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026092314200990400_jiag257-B9","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/QAI.0000000000003787","article-title":"Doravirine resistance patterns identified through week 192 in the DRIVE-FORWARD and DRIVE-AHEAD phase 3 clinical trials","volume":"101","author":"Orkin","year":"2026","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026092314200990400_jiag257-B10","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0140-6736(25)01945-2","article-title":"Switch to fixed-dose doravirine (100 mg) and islatravir (0.25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial","volume":"407","author":"Orkin","year":"2026","journal-title":"Lancet"},{"key":"2026092314200990400_jiag257-B11","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(25)01948-8","article-title":"Switch to fixed-dose doravirine (100 mg) and islatravir (0.25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial","volume":"407","author":"Colson","year":"2026","journal-title":"Lancet"},{"key":"2026092314200990400_jiag257-B12","doi-asserted-by":"crossref","first-page":"e0013322","DOI":"10.1128\/aac.00133-22","article-title":"Islatravir has a high barrier to resistance and exhibits a differentiated resistance profile from approved nucleoside reverse transcriptase inhibitors (NRTIs)","volume":"66","author":"Diamond","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092314200990400_jiag257-B13","doi-asserted-by":"crossref","first-page":"e0116721","DOI":"10.1128\/AAC.01167-21","article-title":"Development of human immunodeficiency virus type 1 resistance to 4'-ethynyl-2-fluoro-2'-deoxyadenosine starting with wild-type or nucleoside reverse transcriptase inhibitor-resistant strains","volume":"65","author":"Cilento","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092314200990400_jiag257-B14","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3851\/IMP2697","article-title":"Delayed emergence of HIV-1 variants resistant to 4'-ethynyl-2-fluoro-2'-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001","volume":"19","author":"Maeda","year":"2014","journal-title":"Antivir Ther"},{"key":"2026092314200990400_jiag257-B15","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.3390\/v16121888","article-title":"Thymidine analogue mutations with M184V significantly decrease phenotypic susceptibility of HIV-1 subtype C reverse transcriptase to islatravir","volume":"16","author":"Byun","year":"2024","journal-title":"Viruses"},{"key":"2026092314200990400_jiag257-B16","doi-asserted-by":"crossref","first-page":"106157","DOI":"10.1016\/j.antiviral.2025.106157","article-title":"Combined doravirine and islatravir cooperate to inhibit NRTI and NNRTI resistant HIV-1 in vitro","volume":"239","author":"Giammarino","year":"2025","journal-title":"Antiviral Res"},{"key":"2026092314200990400_jiag257-B17","author":"Grobler"},{"key":"2026092314200990400_jiag257-B18","author":"Pham"},{"key":"2026092314200990400_jiag257-B19","doi-asserted-by":"crossref","first-page":"ofad146","DOI":"10.1093\/ofid\/ofad146","article-title":"HIV-1 DNA testing in viremic patients identifies more drug resistance than HIV-1 RNA testing","volume":"10","author":"Curanovic","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026092314200990400_jiag257-B20","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1128\/AAC.44.4.920-928.2000","article-title":"A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1","volume":"44","author":"Petropoulos","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092314200990400_jiag257-B21","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/nar\/gkg100","article-title":"Human immunodeficiency virus reverse transcriptase and protease sequence database","volume":"31","author":"Rhee","year":"2003","journal-title":"Nucleic Acids Res"},{"key":"2026092314200990400_jiag257-B22","first-page":"457","article-title":"2025 update of the drug resistance mutations in HIV-1","volume":"33","author":"Wensing","year":"2025","journal-title":"Top Antivir Med"},{"key":"2026092314200990400_jiag257-B23","author":"Colson"},{"key":"2026092314200990400_jiag257-B24","author":"Mngqibisa"},{"key":"2026092314200990400_jiag257-B25","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/S2352-3018(24)00030-4","article-title":"Switch to fixed-dose doravirine (100 mg) with islatravir (0.75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial","volume":"11","author":"Mills","year":"2024","journal-title":"Lancet HIV"},{"key":"2026092314200990400_jiag257-B26","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1016\/S2352-3018(24)00031-6","article-title":"Switch to fixed-dose doravirine (100 mg) with islatravir (0.75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial","volume":"11","author":"Molina","year":"2024","journal-title":"Lancet HIV"},{"key":"2026092314200990400_jiag257-B27","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1054-3589(07)56006-0","article-title":"Development of protease inhibitors and the fight with drug-resistant HIV-1 variants","volume":"56","author":"Mitsuya","year":"2008","journal-title":"Adv Pharmacol"},{"key":"2026092314200990400_jiag257-B28","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/infdis\/jiq167","article-title":"Differential persistence of transmitted HIV-1 drug resistance mutation classes","volume":"203","author":"Jain","year":"2011","journal-title":"J Infect Dis"},{"key":"2026092314200990400_jiag257-B29","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1093\/jac\/dky130","article-title":"Dynamics of drug resistance-associated mutations in HIV-1 DNA reverse transcriptase sequence during effective ART","volume":"73","author":"Nouchi","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2026092314200990400_jiag257-B30","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1002\/j.1460-2075.1996.tb00777.x","article-title":"Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme","volume":"15","author":"Back","year":"1996","journal-title":"EMBO J"},{"key":"2026092314200990400_jiag257-B31","author":"Teyssou"},{"key":"2026092314200990400_jiag257-B32","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1093\/cid\/ciaf161","article-title":"Utilizing HIV proviral DNA to assess for the presence of HIV drug resistance","volume":"81","author":"Wensing","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026092314200990400_jiag257-B33","doi-asserted-by":"crossref","first-page":"105870","DOI":"10.1016\/j.jcv.2025.105870","article-title":"Detection of HIV-1 drug resistance in RNA and proviral DNA genotyping is variable both longitudinally and during repeat testing","volume":"181","author":"D'Antoni","year":"2025","journal-title":"J Clin Virol"},{"key":"2026092314200990400_jiag257-B34","doi-asserted-by":"crossref","first-page":"S398","DOI":"10.1093\/ofid\/ofaa439.883","article-title":"691. Results of repeat HIV-1 DNA resistance tests are highly concordant","volume":"7","author":"Curanovic","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2026092314200990400_jiag257-B35","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1093\/jac\/dkaf353","article-title":"How should APOBEC3-induced resistance mutations be considered in the management of antiretroviral therapy?","volume":"80","author":"Gilbert","year":"2025","journal-title":"J Antimicrob Chemother"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiag257\/68432247\/jiag257.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/234\/3\/e466\/68432247\/jiag257.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/234\/3\/e466\/68432247\/jiag257.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:20:17Z","timestamp":1790187617000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/234\/3\/e466\/8698087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,5,29]]},"published-print":{"date-parts":[[2026,9,23]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiag257","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,15]]},"published":{"date-parts":[[2026,5,29]]}}}